Listen
FLEBOGAMMA (normal human immunoglobulin) - Measles pre/post exposure
Reason for request
Summary of opinion
Favourable opinion for reimbursement in measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (2 to 18 years) in whom active immunisation is contraindicated or not advised.
No clinical added value in the therapeutic strategy.
Clinical Benefit
| Substantial |
The clinical benefit of FLEBOGAMMA DIF 50 mg/ml and 100 mg/ml (normal human immunoglobulin) solution for infusion is substantial in measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (2 to 18 years) in whom active immunisation is contraindicated or not advised. |
Clinical Added Value
| no clinical added value |
The medicinal products FLEBOGAMMA DIF 50 mg/ml and 100 mg/ml (normal human immunoglobulin) provide no clinical added value (CAV V) in the management of measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (2 to 18 years) in whom active immunisation is contraindicated or not advised. |
